Natural Capsules Ltd
Natural Capsules Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Capsule business topline expected to reach Rs. Capsule business topline expected to reach Rs.
From Natural Capsules Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Capsule business topline expected to reach Rs. 235-240 crores with current and upcoming capacity expansions (Page 19, 21).
- Capsule segment growing consistently at about 6% annually in India and 4% internationally (Page 16).
- HPMC capsule sales are targeted to increase, potentially raising EBITDA margins to 16%-18%, and eventually aiming for 20% with capacity utilization improvements (Page 22, 16).
- Exports and substitution of low-end customers with higher-value clients expected to drive revenue growth beyond industry average (Page 16).
- API division aims for Rs. 40 crores revenue in FY’26 but is currently facing technical challenges limiting growth; potential to scale after resolving fermentation yield issues (Pages 9, 15).
2 more points from Natural Capsules Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Natural Capsules Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Natural Capsules is progressing confidently with its capital expenditure program.
- The new HPMC production line is on schedule for commissioning by the end of Q2 FY'26.
- This capacity addition aims to fulfill growing customer demand for different capsule sizes and increase export volumes once tariff issues clarify.
- The company plans to convert some gelatin capsule lines into HPMC lines if demand further increases.
- Competitors like ACG and Healsee Group are investing $100 million and $70 million respectively in US-based HPMC capsule plants, which will take time; by then, market demand is expected to rise.
2 more points from Natural Capsules Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Natural Capsules Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the exact current or expected order book or pending orders in numeric detail.
- There is discussion about demand and volume recovery, especially in the US and other international markets, with some slowdowns due to tariffs and regulatory issues.
- The Mexico export order is ongoing but volumes are below expectations.
- Distributors remain confident of demand recovery despite tariff challenges.
- The company is commissioning new HPMC lines to meet customer demand.
2 more points from Natural Capsules Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Natural Capsules Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹58 Cr, net loss ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Natural Capsules's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Natural Capsules Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Natural Capsules Ltd Q2 FY26 results?
Capsule business topline expected to reach Rs. Capsule business topline expected to reach Rs.
What is Natural Capsules Ltd share price analysis?
Natural Capsules Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹154 Cr. Investors should review the full earnings analysis for detailed insights.
Is Natural Capsules Ltd planning capital expenditure?
Natural Capsules is progressing confidently with its capital expenditure program.
Keep Natural Capsules Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.